Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 7/20 | 0.69 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.69 |
| ▸ | HTR3B | O95264 | 3/20 | 0.69 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.69 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.69 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.69 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.69 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.69 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.69 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.69 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.69 |
| ▸ | HRH1 | P35367 | 1/20 | 0.69 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.69 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.69 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.69 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.43 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6888233 | 1.00 | HTR3A (0.69) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL14017444 | 0.94 | HTR3A (0.60) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL3177266 | 0.94 | HTR3A (0.60) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL6886540 | 0.83 | CHRNA3 (0.71) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL6892215 | 0.83 | CHRNA3 (0.71) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL6887440 | 0.82 | CHRNA7 (0.69) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL6891582 | 0.82 | HTR3A (0.69) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL2187255 | 0.82 | CHRNA3 (0.69) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL2188457 | 0.82 | CHRNA3 (1.00) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL6887585 | 0.82 | HTR3A (0.69) | HTR3AHTR3EHTR3BHTR3DHTR3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170224665-A1 | SELECTIVE HIGH AFFINITY ALFA3BETA4 NICOTINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | Astraea Therapeutics (US) | 2017-08-10 | — | — | US | disclosed |
| US-20170224665-A1 | SELECTIVE HIGH AFFINITY ALFA3BETA4 NICOTINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | Astraea Therapeutics (US) | 2017-08-10 | — | — | US | disclosed |
| US-9670198-B2 | Nicotinic acetylcholine receptor modulators | ASTRAEA THERAPEUTICS, LLC (US) | 2017-06-06 | — | — | US | disclosed |
| US-9670198-B2 | Nicotinic acetylcholine receptor modulators | ASTRAEA THERAPEUTICS, LLC (US) | 2017-06-06 | — | — | US | disclosed |
| US-9062042-B2 | Nicotinic acetylcholine receptor modulators | ASTRAEA THERAPEUTICS, LLC (US) | 2015-06-23 | — | — | US | disclosed |
| US-20150148541-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | Astraea Therapeutics (US) | 2015-05-28 | — | — | US | disclosed |
| US-20150148541-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | Astraea Therapeutics (US) | 2015-05-28 | — | — | US | disclosed |
| US-20110172264-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | ASTRAEA THERAPEUTICS, LLC | 2011-07-14 | — | — | US | disclosed |
| WO-2011085389-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | ASTRAEA THERAPEUTICS, LLC (US) | 2011-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172264-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | CHRNA4, CHRNA3, CHRNA6 | HTR3A 51/4885HTR3E 139/4885HTR3B 81/4885 |
| US-20170224665-A1 | SELECTIVE HIGH AFFINITY ALFA3BETA4 NICOTINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | CHRNA3, CHRNA4, CHRNB3 | HTR3A 65/4885HTR3E 181/4885HTR3B 56/4885 |
| US-20150148541-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | CHRNA3, CHRNA4, CHRNA2 | HTR3A 68/4885HTR3E 172/4885HTR3B 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.